Liver Transplantation Clinical Trial
Official title:
Validity of Mini Fluid Challenge to Assess Fluid Responsiveness Post Liver Transplantation
our study aim to assess the validity of using mini fluid challenge to assess the volaemic status of patients after liver transplantation
After approval of institutional ethical committee and after informed patient consent,
patients fulfilling criteria will be involved. Upon ICU admission, patients will be connected
to full monitoring and confirming patient hemodynamic stability and no active bleeding
through drains. Patients will be in supine position and baseline readings will be recorded.
Fluid responsiveness will be assessed with mini fluid challenge by 150 ml of albumin 5% given
over 1 minute. After fluid administration stroke volume (SV) assessed by trans thoracic echo
(TTE) and other hemodynamic parameters will be recorded. Remaining 350 ml of albumin 5% will
be continued over 14 minute to have total volume given 500 ml. after fluid administration SV
and other parameters will be recorded. The fluid challenge will be given intravenously via a
specific wide pore venous line. Fluid responsiveness will be defined as an increase in the SV
by 15% after the infusion of fluid.
TT Echo Examination:
A single LVOT diameter will be measured for each patient as the distance between the
inflection points at the base of the aortic valve cusps from the left parasternal long axis
view during systole.
Assuming a circular cross section, the LVOT area will be calculated from the LVOT diameter
as:
π X (LVOT diameter/ 2)2 = (LVOT diameter)2 X 0.785 Pulse wave Doppler sampling cursor will be
placed in the middle of the LVOT immediately proximal to the aortic valve in 5 chamber apical
view.
The sonographer manually will trace the velocity-time envelope (VTI). SV values will be
calculated by multiplying VTI by cross sectional area.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 |